# Ketamine and Epigenetic Aging

> **NCT05294835** · PHASE2 · UNKNOWN · sponsor: **TruDiagnostic** · enrollment: 20 (estimated)

## Conditions studied

- Depression
- Post Traumatic Stress Disorder

## Interventions

- **DRUG:** Ketamine

## Key facts

- **NCT ID:** NCT05294835
- **Lead sponsor:** TruDiagnostic
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-04-01
- **Primary completion:** 2022-12-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2022-09-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05294835

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05294835, "Ketamine and Epigenetic Aging". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05294835. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*